Peginesatide
| Clinical data | |
|---|---|
| Trade names | Omontys |
| AHFS/Drugs.com | Omontys |
| License data | |
| Routes of administration | Subcutaneous, intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem SID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEBI | |
| Chemical and physical data | |
| Formula | C231H350N62O58S6[C2H4O]n |
| Molar mass | 45 kg/mol |
Peginesatide[2] (INN/USAN, trade name Omontys, formerly Hematide), developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin.
It was approved by the U.S. Food and Drug Administration for treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.[3][4] On February 23, 2013, Affymax and Takeda issued a press release indicating that they were recalling all batches of peginesatide from the market.[5] On June 16, 2014, Affymax and Takeda issued a press release stating that Takeda will work with the FDA to withdraw the peginesatide New Drug Application.[6]
Two randomized controlled trials published in 2013 found that the effectiveness of peginesatide was not inferior to epoetin for patients receiving dialysis (the EMERALD study),[7] or to darbepoetin for patients with chronic kidney disease who were not receiving dialysis (the PEARL study).[8] However, the safety endpoint of cardiovascular events and death was worse for peginesatide than for darbepoetin in the PEARL study.
Medical uses
[edit]The FDA approved the use of peginesatide for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.[citation needed]
Chemistry and mechanism of action
[edit]Peginesatide is a synthetic peptide, attached to polyethylene glycol ("PEGylated").[9] It mimics the structure of erythropoietin, the human glycoprotein which promotes red blood cell development.
Related drugs
[edit]The erythropoietin analogs currently used to treat anemia in the United States are epoetin alfa (sold under the names Procrit and Epogen) and darbepoetin alfa (which is a more glycosylated form of epoetin, sold under the name Aranesp). There are similar biologic agents, such as Mircera (a monoPEGylated erythropoietin-beta), sold by Roche in Europe, Chugai in Japan, and VFMCRP in the United States.[citation needed]
References
[edit]- ^ Statement On A Nonproprietary Name Adopted By The USAN Council: Peginesatide
- ^ "Affymax, Inc Homepage". Archived from the original on December 21, 2011. Retrieved December 7, 2011.
- ^ "Omontys (peginesatide): Official site for US physicians". Affymax and Takeda. Archived from the original on May 1, 2012. Retrieved April 29, 2012.
- ^ Yao S (March 27, 2012). "FDA approves Omontys to treat anemia in adult patients on dialysis" (press release). US FDA. Retrieved April 29, 2012.
- ^ FDA alerts health care providers of recall of anemia drug Omontys. U.S. Food and Drug Administration [1]
- ^ Affymax and Takeda Announce Termination of Omontys® (peginesatide) Product Collaboration and License Agreement. Takeda will withdraw the Omontys U.S. New Drug Application (NDA)[2]
- ^ Fishbane S, Schiller B, Locatelli F, Covic AC, Provenzano R, Wiecek A, Levin NW, Kaplan M, Macdougall IC, Francisco C, Mayo MR, Polu KR, Duliege AM, Besarab A (January 2013). "Peginesatide in patients with anemia undergoing hemodialysis". N. Engl. J. Med. 368 (4): 307–19. doi:10.1056/NEJMoa1203165. hdl:10486/664909. PMID 23343061.
- ^ Macdougall IC, Provenzano R, Sharma A, Spinowitz BS, Schmidt RJ, Pergola PE, Zabaneh RI, Tong-Starksen S, Mayo MR, Tang H, Polu KR, Duliege AM, Fishbane S (January 2013). "Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis". N. Engl. J. Med. 368 (4): 320–32. doi:10.1056/NEJMoa1203166. PMID 23343062.
- ^ Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, Schatz PJ, Okamoto DM, Naso R, Duliege AM (September 2006). "Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers". Blood. 108 (6): 1830–4. doi:10.1182/blood-2006-04-015818. PMID 16720830.